Modafinil in Diurnal Sleepiness. A Study of 123 Patients

Laffont, F; Mayer, G; Minz, M

doi:10.1093/sleep/17.suppl_8.s113

Cited by 31 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These effects have been underestimated in the literature. Studies that conclude that use of modafinil in clinical conditions has minimal or absent autonomic cardiovascular activation [23][24][25][26] were generally not undertaken under optimal control conditions (abstinence of concurrent drugs, caffeine, alcohol, and nicotine, strict dietary sodium and potassium balance, and hospitalization to ensure control of food intake and physical activity). Results are meansϮSEM.…”

Section: Discussionmentioning

confidence: 99%

Modafinil Elicits Sympathomedullary Activation

et al. 2005

View full text Add to dashboard Cite

Abstract-The autonomic effects of modafinil (Provigil), a psychostimulant widely used to attenuate fatigue and promote wakefulness, are currently unexplored. We assessed the effect of modafinil on autonomic nervous system. We compared oral modafinil (400 mgϫ1) versus placebo in 12 healthy hospitalized normal subjects in a randomized double-blind, placebo-controlled cross-over study for 3 days each with subjects in 150 mEq sodium, 70 mEq potassium balance at the

show abstract

Section: Discussionmentioning

confidence: 99%

Modafinil Elicits Sympathomedullary Activation

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Modafinil, a functional stimulant, is used to treat disorders of excessive sleepiness, such as narcolepsy or idiopathic hypersomnia (Bastuji and Jouvet, 1988;Billiard et al, 1994;Laffont et al, 1994).…”

Section: Modafinilmentioning

confidence: 99%

New treatments for cocaine dependence: a focused review

Karila

Gorelick

Weinstein³

et al. 2007

Int. J. Neuropsychopharm.

166

116

View full text Add to dashboard Cite

Cocaine, already a significant drug problem in North and South America, has become a more prominent part of the European drug scene. Cocaine dependence has major somatic, psychological, psychiatric, socio-economic, and legal implications. No specific effective pharmacological treatment exists for cocaine dependence. Recent advances in neurobiology have identified various neuronal mechanisms implicated in cocaine addiction and suggested several promising pharmacological approaches. Data were obtained from Medline, EMBASE, and PsycINFO searches of English-language articles published between 1985 and June 2007 using the key words: cocaine, addiction, cocaine dependence, clinical trials, pharmacotherapy(ies) singly and in combination. Large well-controlled studies with appropriate statistical methods were preferred. Pharmacological agents such as GABA agents (topiramate, tiagabine, baclofen and vigabatrin) and agonist replacement agents (modafinil, disulfiram, methylphenidate) seem to be the most promising in treatment of cocaine dependence. The results from trials of first- and second-generation neuroleptics are largely negative. Aripiprazole, a partial dopaminergic agonist that may modulate the serotonergic system, shows some promise. Preliminary results of human studies with anti-cocaine vaccine, N-acetylcysteine, and ondansetron, are promising, as are several compounds in preclinical development. While no medication has received regulatory approval for the treatment of cocaine dependence, several medications marketed for other indications have shown efficacy in clinical trials. An anti-cocaine vaccine and several compounds in preclinical development have also shown promise. Findings from early clinical trials must be confirmed in larger, less selective patient populations.

show abstract

“…Most notably, modafinil has been demonstrated to be a safe and effective, long-term treatment modality for narcolepsy (e.g. Bastuji and Jouvet, 1988;Boivin et al, 1993;Billiard et al, 1994;Broughton et al, 1997;Laffont et al, 1994;Moldofsky et al, 2000) and related clinical sleep disorders [e.g. idiopathic hypersomnia and excessive daytime sleepiness (EDS) associated with obstructive sleep apnoea (OSA)].…”

Section: Introductionmentioning

confidence: 99%

Effects of modafinil on cognitive and meta‐cognitive performance

Baranski

Pigeau

Dinich

et al. 2004

Human Psychopharmacology

112

View full text Add to dashboard Cite

The stimulant modafinil has proved to be an effective treatment modality for narcolepsy and related sleep disorders and is also being studied for use during sustained military operations to ameliorate the effects of fatigue due to sleep loss. However, a previous study reported that a relatively large, single dose of modafinil (300 mg), administered to already sleep-deprived individuals, caused participants to overestimate their cognitive abilities (i.e. 'overconfidence'). Because the predominant application of modafinil is in otherwise healthy, non-sleep-deprived individuals, the present study investigated the generality of modafinil-induced overconfidence in a group of 18 healthy, non sleep-deprived adults. The design involved a double-blind, placebo controlled, fully within-subjects manipulation of placebo and modafinil (4 mg/kg: approximately 300 mg, on average) over three 50-min cognitive testing sessions (i.e. before drug ingestion, and at 90 and 180 min after drug ingestion). The cognitive task battery included subjective assessments of mood, fatigue, affect, vigor and motivation, and cognitive assessments of serial reaction time, logical reasoning, visual comparison, mental addition and vigilance. In addition, trial-by-trial confidence judgements were obtained for two of the cognitive tasks and more global, task level assessments of performance were obtained for four of the cognitive tasks. Relative to placebo, modafinil improved fatigue levels, motivation, reaction time and vigilance. In terms of self-assessments of cognitive performance, both the placebo and modafinil conditions were 'well calibrated' on trial-by-trial confidence judgements, showing neither marked over- nor under-confidence. Of note, the modafinil condition displayed a non-significant tendency towards 'overconfidence' for task-level assessments of performance. The present findings highlight the need for continued research on the many complex interactions involving fatigue states, occasional versus long-term stimulant use, and subjective assessments of fatigue and cognitive performance.

show abstract

Modafinil in Diurnal Sleepiness. A Study of 123 Patients

Cited by 31 publications

References 0 publications

Modafinil Elicits Sympathomedullary Activation

Modafinil Elicits Sympathomedullary Activation

New treatments for cocaine dependence: a focused review

Effects of modafinil on cognitive and meta‐cognitive performance

Contact Info

Product

Resources

About